ImmunoCellular Therapeutics Probability of Future Pink Sheet Price Finishing Over 0.6
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
ImmunoCellular |
ImmunoCellular Therapeutics Target Price Odds to finish over 0.6
The tendency of ImmunoCellular Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 0.60 or more in 90 days |
| 0.47 | 90 days | 0.60 | about 76.25 |
Based on a normal probability distribution, the odds of ImmunoCellular Therapeutics to move over $ 0.60 or more in 90 days from now is about 76.25 (This ImmunoCellular Therapeutics probability density function shows the probability of ImmunoCellular Pink Sheet to fall within a particular range of prices over 90 days) . Probability of ImmunoCellular Therapeutics price to stay between its current price of $ 0.47 and $ 0.60 at the end of the 90-day period is about 18.73 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 3.36 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ImmunoCellular Therapeutics will likely underperform. Additionally ImmunoCellular Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. ImmunoCellular Therapeutics Price Density |
| Price |
Predictive Modules for ImmunoCellular Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ImmunoCellular Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ImmunoCellular Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ImmunoCellular Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ImmunoCellular Therapeutics is not an exception. The market had few large corrections towards the ImmunoCellular Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ImmunoCellular Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ImmunoCellular Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.06 | |
β | Beta against Dow Jones | 3.36 | |
σ | Overall volatility | 0.14 | |
Ir | Information ratio | -0.07 |
ImmunoCellular Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ImmunoCellular Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ImmunoCellular Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ImmunoCellular Therapeutics is not yet fully synchronised with the market data | |
| ImmunoCellular Therapeutics has some characteristics of a very speculative penny stock | |
| ImmunoCellular Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ImmunoCellular Therapeutics currently holds about 933.15 K in cash with (2.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 95.0% of the company shares are held by company insiders |
ImmunoCellular Therapeutics Technical Analysis
ImmunoCellular Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. ImmunoCellular Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ImmunoCellular Therapeutics. In general, you should focus on analyzing ImmunoCellular Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
ImmunoCellular Therapeutics Predictive Forecast Models
ImmunoCellular Therapeutics' time-series forecasting models is one of many ImmunoCellular Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary ImmunoCellular Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about ImmunoCellular Therapeutics
Checking the ongoing alerts about ImmunoCellular Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ImmunoCellular Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| ImmunoCellular Therapeutics is not yet fully synchronised with the market data | |
| ImmunoCellular Therapeutics has some characteristics of a very speculative penny stock | |
| ImmunoCellular Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ImmunoCellular Therapeutics currently holds about 933.15 K in cash with (2.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 95.0% of the company shares are held by company insiders |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |